drugset

drugset / Trial / NCT05738850

Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants

NCT05738850 ↗

Phase 1 Completed 104 enrolled AbbVie Gedeon Richter Ltd. · collab

RandomizedSequentialQuadruple-blindTreatment

Summary

The main objective of this study is to assess pharmacokinetics, safety, and tolerability of ABBV-932 in healthy adult participants.

Timeline

Start: 2023-02-15
Primary completion: 2024-05-31
Completion: 2024-05-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ABBV-932	Unknown	—	Oral

Indications